Literature DB >> 11460596

The new classification of diabetes mellitus and IGT: a critical approach.

K Borch-Johnsen1.   

Abstract

In 1999 WHO published the new recommendations for diagnostic criteria for diabetes. The same publication introduced several new categories including the first proposal for diagnostic criteria for the metabolic syndrome. Also, WHO established a new category labelled "impaired fasting glycaemia", and thereafter this new group and the already established impaired glucose tolerance was combined as a common entity labelled "impaired glucose regulation".--These recommendations from WHO followed a decision in the American Diabetes Association to lower the diagnostic plasma glucose threshold for diabetes in the fasting state from 7.8 to 7.0 mmol/l and to use fasting values as the diagnostic test for diabetes. The suggested changes in the diagnostic criteria will include a new group of individuals as having diabetes, while others may be left undiagnosed if fasting glucose values are used as the only diagnostic criteria. The consequence of this has been analysed by several groups including the collaborative European activity (the DECODE-study).--This review summarises the findings. One major problem is that if fasting glucose values are used as the only diagnostic criteria in screening for diabetes, approximately one third of the diabetic individuals will be left undiagnosed. Furthermore, this group is the group of diabetic patients that have the highest mortality from cardiovascular disease and stroke, and the group with the worst cardiovascular risk profile compared to individuals with elevated fasting glucose values alone. This observation raises the need for a continued use of the oral glucose tolerance test in selected groups.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11460596     DOI: 10.1055/s-2001-18572

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  7 in total

1.  Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease.

Authors:  Takhar Kasumov; John M Edmison; Srinivasan Dasarathy; Carole Bennett; Rocio Lopez; Satish C Kalhan
Journal:  Metabolism       Date:  2010-09-23       Impact factor: 8.694

Review 2.  What is the relationship between exercise and metabolic abnormalities? A review of the metabolic syndrome.

Authors:  Sean Carroll; Mike Dudfield
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

Review 3.  Cardiovascular diseases and type 2 diabetes in Bangladesh: a systematic review and meta-analysis of studies between 1995 and 2010.

Authors:  Nazmus Saquib; Juliann Saquib; Tahmeed Ahmed; Masuma Akter Khanam; Mark R Cullen
Journal:  BMC Public Health       Date:  2012-06-13       Impact factor: 3.295

4.  Low serum cartonectin/CTRP3 concentrations in newly diagnosed type 2 diabetes mellitus: in vivo regulation of cartonectin by glucose.

Authors:  Bo Ban; Bo Bai; Manman Zhang; Jiamiao Hu; Manjunath Ramanjaneya; Bee K Tan; Jing Chen
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

5.  CTRP3 is a novel biomarker for diabetic retinopathy and inhibits HGHL-induced VCAM-1 expression in an AMPK-dependent manner.

Authors:  Zheyi Yan; Jianli Zhao; Lu Gan; Yanqing Zhang; Rui Guo; Xiaoming Cao; Wayne Bond Lau; Xin Ma; Yajing Wang
Journal:  PLoS One       Date:  2017-06-20       Impact factor: 3.240

6.  Circulating C1q complement/TNF-related protein (CTRP) 1, CTRP9, CTRP12 and CTRP13 concentrations in Type 2 diabetes mellitus: In vivo regulation by glucose.

Authors:  Bo Bai; Bo Ban; Zunjing Liu; Man Man Zhang; Bee Kang Tan; Jing Chen
Journal:  PLoS One       Date:  2017-02-16       Impact factor: 3.240

7.  Prevalence of Risk Factors for Cardiovascular Diseases in Bangladesh: A Systematic Review and Meta-Analysis.

Authors:  Kaniz Fatema; Nicholas Arnold Zwar; Abul Hasnat Milton; Liaquat Ali; Bayzidur Rahman
Journal:  PLoS One       Date:  2016-08-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.